# EDGAR Filing Document

**Accession Number:** 0001659617
**File Stem:** 0000000000-25-006260
**Filing Date:** 2025-6
**Character Count:** 4206
**Document Hash:** c909b1c47f9531318d73ee87936ab82c
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000000000-25-006260.hdr.sgml**: 20250829

**ACCESSION NUMBER**: 0000000000-25-006260

**CONFORMED SUBMISSION TYPE**: UPLOAD

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20250613

**FILED FOR**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Moleculin Biotech, Inc.
- **CENTRAL INDEX KEY:** 0001659617
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 474671997
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** UPLOAD
- **SEC FILE NUMBER:** 377-08038

**BUSINESS ADDRESS:**
- **STREET 1:** 5300 MEMORIAL DRIVE
- **STREET 2:** SUITE 950
- **CITY:** HOUSTON
- **STATE:** TX
- **ZIP:** 77007
- **BUSINESS PHONE:** 713-300-5160

**MAIL ADDRESS:**
- **STREET 1:** 5300 MEMORIAL DRIVE
- **STREET 2:** SUITE 950
- **CITY:** HOUSTON
- **STATE:** TX
- **ZIP:** 77007
**PUBLIC REFERENCE ACCESSION NUMBER**: 0001437749-25-018355

## Text-Extract

```

                                                            June 13, 2025

Walter V. Klemp
President, Chief Executive Officer and Chairman
Moleculin Biotech, Inc.
5300 Memorial Drive, Suite 950
Houston, TX 77007

       Re: Moleculin Biotech, Inc.
           Amendment No. 2 to Registration Statement on Form S-1
           Filed June 11, 2025
           File No. 333-287727
Dear Walter V. Klemp:

     We have reviewed your amended registration statement and have the
following
comments.

        Please respond to this letter by amending your registration statement
and providing
the requested information. If you do not believe a comment applies to your
facts and
circumstances or do not believe an amendment is appropriate, please tell us why
in your
response.

       After reviewing any amendment to your registration statement and the
information
you provide in response to this letter, we may have additional comments. Unless
we note
otherwise, any references to prior comments are to comments in our June 10,
2025 letter.

Amendment No. 2 to Registration Statement on Form S-1
Risk Factors Related to this Offering, page 6

1.     We note your revised risk factor disclosure on page 8 regarding an
existing
       stockholders' equity continued listing deficiency. In light of your
current stock price,
       the dilution from this offering, and the floor price for the Series E
warrant reset,
       please add a risk factor addressing the potential for a continued
listing deficiency
       related to your bid price. To the extent that a reverse stock split
would likely be
       required to address a bid price deficiency, please address risks related
to conducting a
       reverse split. Without limitation, please explain, if true, that a
reverse stock split
       would trigger a reset to the Series E warrants potentially resulting in
a significant
       decrease to the exercise price of the warrants and significant increase
to the number of
       common shares underlying the Series E warrants.
 June 13, 2025
Page 2

2.     Please revise to discuss, as applicable, risks related to Nasdaq's
potential use of
       its discretionary authority under Listing Rule 5101 to delist a
company's securities
       based on public interest concerns raised by the issuance of warrants
with features that
       could result in substantial dilution to shareholders.
Duration and Exercise Price, page 17

3.     We note your revised disclosure in response to prior comment 2. Please
revise to
       clarify, if true, that the 160,714,286 figure is the maximum number of
common shares
       underlying the warrants regardless of how many times the reset provision
is triggered
       in the future.
       Please contact Daniel Crawford at 202-551-7767 or Joe McCann at
202-551-6262
with any other questions.

                                                            Sincerely,

                                                            Division of
Corporation Finance
                                                            Office of Life
Sciences
cc:   Cavas Pavri, Esq.

```

### Attached PDF Documents

**Attachment 1:** `filename1`

_No text found in this document._